These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 29183864

  • 1. Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab.
    Blumenthal DT, Kanner AA, Aizenstein O, Cagnano E, Greenberg A, Hershkovitz D, Ram Z, Bokstein F.
    World Neurosurg; 2018 Feb; 110():e727-e737. PubMed ID: 29183864
    [Abstract] [Full Text] [Related]

  • 2. The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment.
    Kambe A, Kitao S, Ochiai R, Hosoya T, Fujii S, Kurosaki M.
    J Neurooncol; 2024 Jan; 166(1):175-183. PubMed ID: 38165552
    [Abstract] [Full Text] [Related]

  • 3. Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.
    Kulinich DP, Sheppard JP, Nguyen T, Kondajji AM, Unterberger A, Duong C, Enomoto A, Patel K, Yang I.
    Acta Neurochir (Wien); 2021 Jul; 163(7):1921-1934. PubMed ID: 33796887
    [Abstract] [Full Text] [Related]

  • 4. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD, Bhamidipati D, Song A, Eldredge-Hindy HB, Siglin J, Dan TD, Champ CE, Zhang I, Bar-Ad V, Kim L, Glass J, Evans JJ, Andrews DW, Werner-Wasik M, Shi W.
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [Abstract] [Full Text] [Related]

  • 5. Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with Bevacizumab-based therapy at diagnosis.
    Salloum R, DeWire M, Lane A, Goldman S, Hummel T, Chow L, Miles L, Sutton M, Stevenson C, Fouladi M, Leach J.
    J Neurooncol; 2015 Feb; 121(3):591-8. PubMed ID: 25433556
    [Abstract] [Full Text] [Related]

  • 6. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
    Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE.
    J Clin Oncol; 2010 Jun 20; 28(18):3069-75. PubMed ID: 20479404
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
    Auer TA, Breit HC, Marini F, Renovanz M, Ringel F, Sommer CJ, Brockmann MA, Tanyildizi Y.
    J Neuroradiol; 2019 Feb 20; 46(1):36-43. PubMed ID: 29733920
    [Abstract] [Full Text] [Related]

  • 8. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab.
    Auer TA, Renovanz M, Marini F, Brockmann MA, Tanyildizi Y.
    J Neurooncol; 2017 Jul 20; 133(3):571-579. PubMed ID: 28555422
    [Abstract] [Full Text] [Related]

  • 9. Utility of intravoxel incoherent motion magnetic resonance imaging and arterial spin labeling for recurrent glioma after bevacizumab treatment.
    Miyoshi F, Shinohara Y, Kambe A, Kuya K, Murakami A, Kurosaki M, Ogawa T.
    Acta Radiol; 2018 Nov 20; 59(11):1372-1379. PubMed ID: 29471670
    [Abstract] [Full Text] [Related]

  • 10. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
    Arvold ND, Shi DD, Aizer AA, Norden AD, Reardon DA, Lee EQ, Nayak L, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Wen PY, Alexander BM.
    J Neurooncol; 2017 Dec 20; 135(3):581-591. PubMed ID: 28975467
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
    Detti B, Scoccianti S, Teriaca MA, Maragna V, Lorenzetti V, Lucidi S, Bellini C, Greto D, Desideri I, Livi L.
    Radiol Med; 2021 Sep 20; 126(9):1249-1254. PubMed ID: 34081269
    [Abstract] [Full Text] [Related]

  • 12. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
    Schernberg A, Dhermain F, Ammari S, Dumont SN, Domont J, Patrikidou A, Pallud J, Dezamis É, Deutsch É, Louvel G.
    Cancer Radiother; 2018 Feb 20; 22(1):9-16. PubMed ID: 29217134
    [Abstract] [Full Text] [Related]

  • 13. Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results.
    Bokstein F, Blumenthal DT, Corn BW, Gez E, Matceyevsky D, Shtraus N, Ram Z, Kanner AA.
    J Neurooncol; 2016 Feb 20; 126(3):551-7. PubMed ID: 26603164
    [Abstract] [Full Text] [Related]

  • 14. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience.
    Gorsi HS, Khanna PC, Tumblin M, Yeh-Nayre L, Milburn M, Elster JD, Crawford JR.
    Pediatr Blood Cancer; 2018 Sep 20; 65(9):e27234. PubMed ID: 29750399
    [Abstract] [Full Text] [Related]

  • 15. Retrospective study of nivolumab for patients with recurrent high grade gliomas.
    Mantica M, Pritchard A, Lieberman F, Drappatz J.
    J Neurooncol; 2018 Sep 20; 139(3):625-631. PubMed ID: 29779086
    [Abstract] [Full Text] [Related]

  • 16. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
    Cha Y, Kim YJ, Lee SH, Kim TM, Choi SH, Kim DW, Park CK, Kim IH, Kim JH, Kim E, Choi B, Kim CY, Kim IA, Heo DS.
    Cancer Res Treat; 2017 Jan 20; 49(1):129-140. PubMed ID: 27188199
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
    Shi W, Blomain ES, Siglin J, Palmer JD, Dan T, Wang Y, Werner-Wasik M, Glass J, Kim L, Bar Ad V, Bhamidipati D, Evans JJ, Judy K, Farrell CJ, Andrews DW.
    J Neurooncol; 2018 Mar 20; 137(1):171-177. PubMed ID: 29235052
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.